Intermittent Catheters - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The intermittent catheters market size is projected to expand from USD 2.71 billion in 2025 and USD 2.86 billion in 2026 to USD 3.84 billion by 2031, registering a CAGR of 6.05% between 2026 to 2031. This report is Segmented by Product Type (Coated, Uncoated), Category (Male, Female, Pediatric), Tip Type (Straight, Coudé, Specialty), Material (PVC, Silicone, Latex, Others), Application (Neurogenic Bladder, Urinary Incontinence, and More), End User, Distribution Channel, Geography (North America, Europe, Asia-Pacific, MEA, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Intermittent Catheters Market Trends and Insights

Rising Neurogenic Bladder Burden

The intermittent catheters market draws durable demand from neurogenic bladder management because bladder dysfunction affects a large share of people with spinal cord injury and a meaningful share of those living with multiple sclerosis. A 2025 study from China showed that intermittent catheterization was the leading bladder management method among chronic spinal cord injury patients, and those using it had fewer urological hospitalizations than those relying on indwelling devices. The same clinical pattern supports recurring demand because the patient base does not use catheters occasionally, but over long periods and often across several care settings. The intermittent catheters market is also influenced by the fact that guideline-discordant measurement practices remain common in hospitalized spinal cord injury care, which leaves room for training support, nurse-led education, and adherence tools from manufacturers. Pediatric demand adds to this base because congenital neurological conditions create a long lifetime of catheter use, which supports steady replacement volume rather than short-cycle treatment demand.

Shift Toward Hydrophilic and Pre-Lubricated Catheters

The intermittent catheters market continues to move toward hydrophilic and pre-lubricated devices because these products are associated with lower urethral trauma and better ease of use in routine self-catheterization. Wellspect expands this direction in 2026 with the LoFric Elle Pro and LoFric Origo Pro launches, both built around 12 smooth eyelets intended to support complete bladder emptying in one flow. Coloplast also reported that its Luja catheter platform was a main contributor to continence care growth, which shows that premium product performance is translating into commercial results rather than remaining only a clinical discussion. The January 2026 CMS coding revision strengthens this shift because coated and non-coated products are no longer treated as one bundled reimbursement category in Medicare billing. The intermittent catheters market is therefore seeing premium conversion supported by both clinical evidence and payment clarity, which is a stronger combination than either factor alone.

High Out-of-Pocket Cost for Premium Catheters

The intermittent catheters market still faces a meaningful affordability barrier because premium hydrophilic devices cost far more than standard uncoated alternatives in systems with weak reimbursement. This price gap matters most where patients buy supplies directly, because the daily and long-duration nature of use turns a product choice into a sustained financial burden. The OIG audit on improper payments also suggests that tighter compliance reviews can narrow reimbursement access for some U.S. beneficiaries, which may indirectly slow premium mix expansion even in a well-funded system. The result is a structural tradeoff in which some patients reuse catheters to control cost, even though reuse weakens the hygiene advantage that supports single-use intermittent protocols. This restraint remains important for the intermittent catheters market because it limits conversion toward higher-value products and keeps lower-cost formats relevant in large patient populations.

Other drivers and restraints analyzed in the detailed report include:

• Reimbursement Support for Disposable Intermittent Catheters
• Closed System Adoption in Infection-Sensitive Care Pathways
• Reuse Behavior and Supply Inconsistency in Price-Sensitive Markets

Segment Analysis

Coated intermittent catheters held 56.21% of the intermittent catheters market share in 2025, which shows how strongly reimbursement support and clinical guidance favor premium formats in established healthcare systems. In the intermittent catheters market, hydrophilic products remain the main volume engine inside coated devices because they are positioned around easier insertion, lower trauma, and cleaner daily use. This is especially visible in North America and Northern Europe, where single-use protocols are more established and where procurement decisions increasingly reflect quality metrics as well as product price. Antimicrobial-coated devices remain a smaller tier, but they are gaining relevance where infection-sensitive care pathways require stronger contamination control during catheter handling and use. The intermittent catheters market also gives coated products a commercial advantage because January 2026 Medicare coding changes now differentiate hydrophilic reimbursement from standard billing categories in a more direct way.

Uncoated catheters are projected to grow at a 6.81% CAGR through 2031, which makes them the fastest-moving product type even though their share base is smaller. That pattern reflects cost substitution in Asia-Pacific, the Middle East and Africa, and Latin America, where affordability still determines much of product choice across hospitals, clinics, and out-of-pocket users. In the intermittent catheters industry, this creates a split between premium innovation in coated devices and steady volume resilience in basic PVC-based products. EU MDR documentation also needs to weigh more heavily on smaller suppliers of uncoated products because compliance costs are harder to absorb in lower-margin categories. As a result, the intermittent catheters market is likely to keep coated devices at the center of premium revenue while uncoated products remain essential for access and volume growth in price-sensitive settings.

Male length catheters accounted for 42.83% share of the intermittent catheters market size in 2025, reflecting the strong male skew in spinal cord injury prevalence and the large installed base of adult male self-catheterization users. This leading position is supported by the fact that spinal cord injury cohorts in large clinical datasets continue to show a high male representation, which feeds long-term demand for standard male length products. Female length products remain strategically important because manufacturers are using compact designs, discreet packaging, and easier handling features to improve adoption among daily users outside institutional settings. Coloplast reported strong uptake for the Luja female catheter in France and the United Kingdom during Q2 2025/26, which suggests that user-centered product design is translating into sales momentum in mature European markets. The intermittent catheters market is therefore seeing category development shaped by anatomy, daily routine, and packaging expectations rather than by length alone.

Pediatric length catheters are projected to rise at a 7.94% CAGR through 2031, which makes them the fastest-growing category in the intermittent catheters market. This growth is supported by expanding pediatric neurology and rehabilitation services, particularly in developing countries where congenital neurological conditions continue to create long-duration catheter users. Children diagnosed with spina bifida or neurogenic bladder often continue catheter use into adulthood, so early diagnosis supports many years of recurring demand rather than a short treatment cycle. The intermittent catheters market also benefits when pediatric lines incorporate smaller diameters, gentler insertion features, and child-friendly packaging, because long-term adherence depends on routine acceptability as much as clinical need. That combination keeps the pediatric segment under stronger strategic focus than its current size alone would suggest.

Straight tip catheters commanded 59.64% share in 2025, which reflects their broad suitability across standard urethral anatomies and their role as the default option in many training protocols. In the intermittent catheters market, straight tip formats remain the main entry point because clinicians commonly begin patients on simpler devices before considering more specialized configurations. Their leadership is also helped by scale, since large hospital and institutional purchasing programs often prefer products that cover a wide range of routine needs with less complexity. This keeps straight tip products central to the recurring demand base across both initial prescriptions and repeat supply cycles. The intermittent catheters market therefore continues to rely on straight tip devices as its broadest-volume tip category.

Coudé tip catheters are projected to expand at a 7.33% CAGR through 2031, driven by patients with benign prostatic hyperplasia, urethral strictures, and post-surgical anatomical difficulty. CMS requires explicit medical necessity documentation for coudé use under the relevant hydrophilic code, which supports tip-specific reimbursement discipline and clearer clinical justification in the U.S. system. Specialty tip products remain smaller, but they are building a place in pediatric and complex neurological care where softer or more tailored designs can reduce insertion difficulty. Remote consultations also support this segment because patients with anatomy-related challenges can reach specialists faster and move to more suitable tip types without as many in-person visits. In the intermittent catheters industry, that gives coudé and specialty formats a narrower but steadily deepening role within premium and clinically differentiated product lines.

Complete Report Scope:

• By Product Type
  • Coated Intermittent Catheters
    • Hydrophilic Coated Catheters
    • Antimicrobial Coated Catheters
  • Uncoated Intermittent Catheters
    • PVC Intermittent Catheters
    • Latex Intermittent Catheters
• By Category
  • Male Length Catheters
  • Female Length Catheters
  • Pediatric Length Catheters
• By Tip Type
  • Straight Tip Catheters
  • Coudé Tip Catheters
  • Specialty Tip Catheters
• By Material
  • PVC
  • Silicone
  • Latex
  • Polyurethane
  • Polyethylene
• By Application
  • Neurogenic Bladder
  • Urinary Retention
  • Urinary Incontinence
  • Spinal Cord Injury
  • Prostate Surgery
  • Multiple Sclerosis
• By End User
  • Hospitals
  • Home Care Settings
  • Ambulatory Surgical Centers
  • Long-Term Care Facilities
  • Specialty Clinics
• By Distribution Channel
  • Institutional Sales
  • Retail Pharmacies
  • Online and Direct-To-Patient
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 33.41% of intermittent catheters market share in 2025, which made it the largest regional block by value. The region leads because the United States combines established reimbursement, high single-use adoption, and a large diagnosed base of neurogenic bladder patients who use intermittent devices over long periods. The January 2026 HCPCS reform is especially important because it gives hydrophilic-coated products clearer billing pathways through codes A4295, A4296, and A4297, which supports coated conversion and direct-to-patient supply. Canada adds stability through structured provincial reimbursement for spinal cord injury and neurogenic bladder care, while Mexico adds a smaller but growing private healthcare demand base. The intermittent catheters market in North America also benefits from earlier adoption of digital support tools that help younger and active self-catheterizing patients stay on routine supply schedules.

Europe was the second-largest regional cluster in the intermittent catheters market in 2025, led by Germany, the United Kingdom, and France. Coloplast identified these countries as key contributors to continence care growth in its H1 2025/26 reporting, which underlines the purchasing strength of their major health systems. Germany's revised 2026 clinical guidance gives the region added institutional support by positioning clean intermittent catheterization as the preferred standard for neurogenic lower urinary tract dysfunction. At the same time, the EU MDR transition is raising documentation and follow-up demands, which gradually favors large suppliers with stronger regulatory infrastructure. Southern and Eastern Europe still offer room for expansion, especially where physician training and patient education remain less developed than in Northern Europe.

The intermittent catheters market size for Asia-Pacific is projected to expand at 7.82% CAGR through 2031, the fastest regional pace in this study. China remains central to that growth because 2025 clinical evidence showed intermittent catheterization as the leading bladder management method among chronic spinal cord injury patients, with fewer urological hospitalizations than indwelling use. India adds momentum through a combination of spina bifida-linked need, broader urology service availability, and rehabilitation access beyond the largest metro centers. Japan supports steady demand through its aging population and its established use base in urinary incontinence and post-prostatectomy care. South Korea and Australia represent premium regional pockets where hydrophilic and compact formats fit well with higher healthcare standards and greater acceptance of self-managed use. Middle East and Africa and South America remain smaller overall, but the GCC shows premium demand growth while Brazil provides a strong clinical adoption base for recurring CIC volume through rehabilitation and public hospital channels.

List of Companies Covered in this Report:

• Adapta Medical, Inc.
• Amsino International, Inc.
• Bactiguard Holding AB
• B. Braun
• Beckton Dickinson
• Boston Scientific
• Cardinal Health
• Coloplast
• Convatec
• Cook Group
• Cure Medical, LLC
• Flexicare
• Hollister
• HR HealthCare, Inc.
• Medline Industries
• Medtronic
• Pennine Healthcare Ltd
• Romsons Group of Industries
• Teleflex
• Wellspect HealthCare

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support